Hendaus Mohamed A
Sidra Medicine, Doha, Qatar.
Weill Cornell Medicine, Education City, Qatar.
J Biomol Struct Dyn. 2021 Jul;39(10):3787-3792. doi: 10.1080/07391102.2020.1767691. Epub 2020 May 20.
The pandemic of COVID-19 (Coronavirus Disease-2019) is an extremely contagious respiratory illness due to a novel coronavirus, SARS-CoV-2. Certain drugs have several protein targets and many illnesses share overlapping molecular paths. In such cases, reusing drugs for more than one objective and finding their novice uses can considerably decrease the time in finding new cures for unforeseen diseases. Remdesivir has been recently a strong candidate for the treatment of Covid-19. In this commentary, we have portrayed the structure of the coronavirus in a simple way as well as the site where remdesivir acts. We have also displayed the ongoing clinical trials, as well as a published study that was conducted on compassionate base. The covid-19 pandemic might wean down by the end of summer 2020, but the risk of seasonality exists. Therefore, future disposal of agents such as remdesivir might be crucial for ensuring an efficient treatment, decrease mortality and allow early discharge.Communicated by Ramaswamy H. Sarma.
2019年冠状病毒病(COVID-19)大流行是一种由新型冠状病毒SARS-CoV-2引起的极具传染性的呼吸道疾病。某些药物有多个蛋白质靶点,许多疾病共享重叠的分子途径。在这种情况下,将药物用于多个目标并发现其新用途可以大大缩短为不可预见的疾病寻找新疗法的时间。瑞德西韦最近一直是治疗COVID-19的有力候选药物。在这篇评论中,我们以简单的方式描绘了冠状病毒的结构以及瑞德西韦的作用位点。我们还展示了正在进行的临床试验以及一项基于同情原则进行的已发表研究。COVID-19大流行可能在2020年夏末减弱,但季节性风险依然存在。因此,未来对瑞德西韦等药物的处置可能对确保有效治疗、降低死亡率和实现早期出院至关重要。由拉马斯瓦米·H·萨尔马传达。